Parsemus Foundation

Treating COVID with Metformin Reduces Long COVID Rates

Retrieved on: 
Friday, June 9, 2023

MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.

Key Points: 
  • MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.
  • The randomized, quadruple-blinded, placebo-controlled clinical trial was the first in the country to study whether these medications could prevent severe outcomes and Long COVID.
  • The trial found that people who took metformin within seven days after the onset of COVID symptoms were 41% less likely to experience Long COVID than those who had placebo—with a 63% reduction if metformin was started within four days.
  • As the first COVID treatment proven to reduce Long COVID in a randomized controlled trial, metformin is safe, accessible and low-cost.

Treating COVID with Metformin Reduces Long COVID Rates

Retrieved on: 
Friday, June 9, 2023

MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.

Key Points: 
  • MINNEAPOLIS, June 9, 2023 /PRNewswire/ -- A new study published in The Lancet Infectious Diseases supported by the Parsemus Foundation found a 41% reduction in Long COVID rates among people who used metformin at the time of COVID infection.
  • The randomized, quadruple-blinded, placebo-controlled clinical trial was the first in the country to study whether these medications could prevent severe outcomes and Long COVID.
  • The trial found that people who took metformin within seven days after the onset of COVID symptoms were 41% less likely to experience Long COVID than those who had placebo—with a 63% reduction if metformin was started within four days.
  • As the first COVID treatment proven to reduce Long COVID in a randomized controlled trial, metformin is safe, accessible and low-cost.

Parsemus Foundation: Common and Affordable Drug Can Drastically Reduce COVID Complications, Study Shows

Retrieved on: 
Tuesday, August 30, 2022

The multi-site COVID-OUT study compared three medications that have been considered promisinglow-dose fluvoxamine, an antidepressant; ivermectin, an antiparasitic drug; and metformin, a low-cost diabetes drug.

Key Points: 
  • The multi-site COVID-OUT study compared three medications that have been considered promisinglow-dose fluvoxamine, an antidepressant; ivermectin, an antiparasitic drug; and metformin, a low-cost diabetes drug.
  • Metformin reduced severe outcomes (hospitalization, emergency room visits, and death) by 42% or 55% if started within 4 days of symptoms.
  • The study included 1,323 individuals over 30 years old at elevated risk of severe outcomes.
  • This would be the first universally available treatment for COVID, giving lower-income countries a tool to combat the disproportionate impact of this disease.

Parsemus Foundation: Metformin Drastically Reduces COVID Hospitalization, Study Shows

Retrieved on: 
Thursday, August 18, 2022

The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.

Key Points: 
  • The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.
  • But you dont know whether its just coincidence until you go back to the beginning, with a rigorous randomized trial.
  • Parsemus Foundation was joined by two larger foundations also eager to see low-cost, globally-accessible medications put to the test.
  • More information on the Parsemus Foundation and the work presented here can be found at: https://www.parsemus.org/humanhealth/covid-19/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005438/en/